Datapoint: Pfizer Scores Atopic Dermatitis Approval for Cibinqo

The FDA last week approved Pfizer’s JAK1 inhibitor Cibinqo for the treatment of moderate to severe atopic dermatitis in adults who have not been able to adequately manage the disease with other medications. The more limited scope of the approval is good news for Sanofi and Regeneron, whose monoclonal antibody Dupixent currently dominants the atopic dermatitis space. The drug currently holds covered or better status for 92% of all insured lives under the pharmacy benefit. 39% of lives have preferred access to Dupixent.

SOURCE: MMIT Analytics, as of 1/19/22

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 17

Datapoint: Michigan Awards Contracts for New Duals Program

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 16

Datapoint: CMS Releases 2025 Star Ratings

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 15

Datapoint: Pfizer Scores Another Hemophilia Nod

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today